Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(40.0%)

Phase 2

2(40.0%)

N/A

1(20.0%)

5Total

Phase 1(2)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05162638Not ApplicableEnrolling By Invitation

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

Role: collaborator

NCT02398500Phase 1Terminated

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

Role: collaborator

NCT02515942Phase 2Completed

CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)

Role: collaborator

NCT02365519Phase 2Completed

LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease

Role: collaborator

NCT02281292Phase 1Withdrawn

A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema

Role: collaborator

All 5 trials loaded